Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of Linafexor in Healthy Subjects
NCT05082779Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of linafexor in Primary Sclerosing Cholangitis (PSC) (11 arms), sponsored by Cascade Pharmaceuticals. Primary endpoints: Single-Dose Pharmacokinetic Parameters at Day 1, Multiple-Dose Pharmacokinetic Parameters at Day 14 and 1 more. Started Oct 2021; status: completed.
02
Drugs
linafexor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT05082779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082779.